Photocure (PHO) - Total Assets
Based on the latest financial reports, Photocure (PHO) holds total assets worth Nkr696.70 Million NOK (≈ $73.31 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Photocure (PHO) net assets for net asset value and shareholders' equity analysis.
Photocure - Total Assets Trend (2000–2024)
This chart illustrates how Photocure's total assets have evolved over time, based on quarterly financial data.
Photocure - Asset Composition Analysis
Current Asset Composition (December 2024)
Photocure's total assets of Nkr696.70 Million consist of 57.4% current assets and 42.6% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr288.83 Million | 39.1% |
| Accounts Receivable | Nkr66.86 Million | 9.1% |
| Inventory | Nkr39.54 Million | 5.4% |
| Property, Plant & Equipment | Nkr36.17 Million | 4.9% |
| Intangible Assets | Nkr95.86 Million | 13.0% |
| Goodwill | Nkr144.00 Million | 19.5% |
Asset Composition Trend (2000–2024)
This chart illustrates how Photocure's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PHO company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Photocure's current assets represent 57.4% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 39.1% of total assets in 2024, up from 7.6% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is cash and equivalents at 39.1% of total assets.
Photocure Competitors by Total Assets
Key competitors of Photocure based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Photocure - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.25 | 5.16 | 5.17 |
| Quick Ratio | 3.87 | 4.73 | 4.80 |
| Cash Ratio | 2.81 | 3.77 | 0.00 |
| Working Capital | Nkr286.51 Million | Nkr321.12 Million | Nkr332.46 Million |
Photocure - Advanced Valuation Insights
This section examines the relationship between Photocure's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.44 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 3.8% |
| Total Assets | Nkr739.09 Million |
| Market Capitalization | $184.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values Photocure's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Photocure's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Photocure (2000–2024)
The table below shows the annual total assets of Photocure from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr739.09 Million ≈ $77.77 Million |
+3.81% |
| 2023-12-31 | Nkr711.97 Million ≈ $74.92 Million |
-0.98% |
| 2022-12-31 | Nkr719.03 Million ≈ $75.66 Million |
-8.94% |
| 2021-12-31 | Nkr789.65 Million ≈ $83.09 Million |
+1.75% |
| 2020-12-31 | Nkr776.05 Million ≈ $81.66 Million |
+201.55% |
| 2019-12-31 | Nkr257.35 Million ≈ $27.08 Million |
+11.31% |
| 2018-12-31 | Nkr231.20 Million ≈ $24.33 Million |
-12.13% |
| 2017-12-31 | Nkr263.10 Million ≈ $27.69 Million |
-7.96% |
| 2016-12-31 | Nkr285.85 Million ≈ $30.08 Million |
+15.24% |
| 2015-12-31 | Nkr248.06 Million ≈ $26.10 Million |
-8.32% |
| 2014-12-31 | Nkr270.58 Million ≈ $28.47 Million |
-10.32% |
| 2013-12-31 | Nkr301.73 Million ≈ $31.75 Million |
-30.31% |
| 2012-12-31 | Nkr432.98 Million ≈ $45.56 Million |
-14.97% |
| 2011-12-31 | Nkr509.18 Million ≈ $53.58 Million |
-0.91% |
| 2010-12-31 | Nkr513.84 Million ≈ $54.07 Million |
+12.47% |
| 2009-12-31 | Nkr456.86 Million ≈ $48.08 Million |
+92.08% |
| 2008-12-31 | Nkr237.85 Million ≈ $25.03 Million |
-21.08% |
| 2007-12-31 | Nkr301.39 Million ≈ $31.72 Million |
-19.72% |
| 2006-12-31 | Nkr375.42 Million ≈ $39.51 Million |
+255.16% |
| 2005-12-31 | Nkr105.70 Million ≈ $11.12 Million |
-39.15% |
| 2004-12-31 | Nkr173.71 Million ≈ $18.28 Million |
-25.57% |
| 2003-12-31 | Nkr233.40 Million ≈ $24.56 Million |
-21.94% |
| 2002-12-31 | Nkr299.01 Million ≈ $31.46 Million |
-6.43% |
| 2001-12-31 | Nkr319.57 Million ≈ $33.63 Million |
-21.06% |
| 2000-12-31 | Nkr404.85 Million ≈ $42.60 Million |
-- |
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more